Research & Development
RedHill Biopharma to submit Talicia for UK marketing authorisation
18 March 2025 - Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq:RDHL) said on Tuesday that it plans to submit a UK Marketing Authorisation Application (MAA) for Talicia, a treatment for Helico...
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
18 March 2025 - French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Tuesday that it has received US Food and Drug Administration (FDA) 510(k) clearance for its VITEK COMPACT...
GRIN Therapeutics' Radiprodil receives Orphan Drug designation
18 March 2025 - GRIN Therapeutics Inc, a developer of therapies to treat serious neurodevelopmental disorders, announced on Monday that the US Food and Drug Administration (FDA) has granted Orphan Dru...
BioArctic receives US FDA orphan drug designation OOPD for exidavnemab
18 March 2025 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Monday that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA)...
Eneboparatide Shows Positive Results in Phase III Trial for Chronic Hypoparathyroidism
17 March 2025 - British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca (LSE:AZN)(STO:AZN)(Nasdaq:AZN) announced on Monday that eneboparatide (AZP-3601), an investigational ...
Precision BioSciences secures IND clearance for gene editing therapy targeting chronic hepatitis B
17 March 2025 - Clinical stage gene editing company Precision BioSciences (Nasdaq:DTIL) announced on Monday that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND...